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Abstract
Phthalate diesters, widely used in flexible plastics and consumer products, have become
prevalent contaminants in the environment. Human exposure is ubiquitous and higher
phthalate metabolite concentrations documented in patients using medications with
phthalate-containing slow release capsules raises concerns for potential health effects.
Furthermore, animal studies suggest that phthalate exposure can modulate circulating
hormone concentrations and thus may be able to adversely affect reproductive physiology and
the development of estrogen sensitive target tissues. Therefore, we conducted a systematic
review of the epidemiological and experimental animal literature examining the relationship
between phthalate exposure and adverse female reproductive health outcomes. The
epidemiological literature is sparse for most outcomes studied and plagued by small sample
size, methodological weaknesses, and thus fails to support a conclusion of an adverse effect
of phthalate exposure. Despite a paucity of experimental animal studies for several phthalates,
we conclude that there is sufficient evidence to suggest that phthalates are reproductive
toxicants. However, we note that the concentrations needed to induce adverse health effects
are high compared to the concentrations measured in contemporary human biomonitoring
studies. We propose that the current patchwork of studies, potential for additive effects and
evidence of adverse effects of phthalate exposure in subsequent generations and at lower
concentrations than in the parental generation support the need for further study.
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Introduction
Phthalates are alkyl diesters of phthalic acid named based on
the lengths of the alkyl chains (Figure 1) and are used to impart
flexibility in plastic or as a matrix in cosmetic products
(Wittassek et al., 2011). Phthalates are not covalently bound to
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Figure 1. The general chemical structure of a
phthalate diester (alkyl chains designated by
R) in addition to the chemical structures of
the more commonly researched phthalates
and major metabolites of the diester.
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the plastic and thus leach into the environment where they are
ubiquitous contaminants (Wittassek et al., 2011).
Environmental sources of exposure include dust and water
(Wittassek et al., 2011). However, the main sources of human
exposure are food and consumer products such as cosmetics
(Wittassek et al., 2011). As a result, human exposure to
phthalates is widespread (Blount et al., 2000; Calafat &
McKee, 2006).
Owing to the extensive use of phthalates in many
commercial products and medical devices as well as broad
environmental contamination, great care needs to be exercised
to avoid sample contamination and ensure accurate exposure
estimates. Specifically, contamination is a potential concern
if materials containing phthalates are used to collect, process
or analyze study subject samples. After absorption, phthalates
are initially metabolized to monoesters which can be
metabolized further and are eventually excreted as glucur-
onides in urine (Wittassek et al., 2011). Phthalates are rapidly
metabolized and eliminated in the urine and quantification
of phthalate monoesters in the urine has become a reliable
biomarker of phthalate exposure. While measuring metabol-
ites in urine is a more valid method of quantification, some
metabolites are more accurate indicators of exposure than
others. For example, the utility of two di-2-ethylhexyl phthal-
ate (DEHP) metabolites, mono-(2-ethyl-5-oxohexyl)
phthalate (MEOHP) and mono-(2-ethyl-5-hydroxyhexyl)
phthalate (MEHHP), were examined as potential DEHP
exposure biomarkers (Barr et al., 2003). These metabolites
are formed by oxidative metabolism of mono-2-ethylhexyl
phthalate (MEHP). Both the range and the mean urinary
MEOHP and MEHHP concentrations in 62 subjects were
on average four-fold higher than those of MEHP; the mean of
the individual ratios of MEHHP/MEOHP, MEHHP/MEHP
and MEOHP/MEHP were 1.4, 8.2 and 5.9, respectively (Barr
et al., 2003). These data suggest that MEOHP and MEHHP
are more sensitive biomarkers of exposure to DEHP than is
MEHP. These findings also suggest a predominant human
metabolic route for DEHP hydrolysis to MEHP followed by
the oxidation of MEHP; they also imply that a similar
mechanism may be relevant for other high-molecular-weight
phthalates, such as di-n-octyl, di-isononyl and di-isodecyl
phthalates (DnOP, DiNP and DiDP). As a result, the selection
of metabolites as biomarkers for the phthalate diesters with
longer alkyl chains should be carefully considered in order to
allow for accurate quantification of exposure.
Based on urinary biomarkers, average human exposures
are estimated to be between 2.32–12 mg/kg/d for diethyl
phthalate (DEP), 0.26–0.88 mg/kg/d butylbenzyl phthalate
(BBP), 0.84–5.22mg/kg/d dibutyl phthalate (DBP), 0.12–
1.4mg/kg/d di-isobutyl phthalate (DiBP), 0.71–4.6mg/kg/d
DEHP and 0.29 mg/kg/d DiNP in German and US populations
(reviewed in Koch & Calafat, 2009). Interestingly, young
women have greater exposure than males of the same age,
possibly due to an increased use of cosmetics (Wittassek
et al., 2011). Exposure may also be substantially higher in
people using medications with slow release capsules in which
phthalates have been employed in their manufacture (Hauser
et al., 2004; Hernandez-Diaz et al., 2009). In a spot urine
sample collected 3 months after a single male subject was
prescribed a mesalamine preparation in which DBP is a
component of the slow release capsule, the concentration of
monobutyl phthalate (MBP), a DBP metabolite, was 16 868
ng/mL (6180mg/g creatinine) (Hauser et al., 2004). This
concentration was more than two orders of magnitude higher
than the 95th percentile for males reported in the 1999–2000
National Health and Nutrition Examination Survey
(NHANES) whereas the patient’s urinary concentrations of
monoethyl phthalate (MEP) (443.7 ng/mL, 162.6mg/g cre-
atinine), MEHP (3.0 ng/mL, 1.1 mg/g creatinine) and mono-
benzyl phthalate (MBzP) (9.3 ng/mL, 3.4 mg/g creatinine), and
thus exposure to DEP, DEHP and BBP were unremarkable
(Hauser et al., 2004). Of the 7999 persons with information on
urinary phthalate concentrations in the NHANES 1999–2004
study, six reported using mesalamine formulations, some of
which may include DBP; the mean urinary concentration
of MBP, the main DBP metabolite, was 50 times higher
among mesalamine users compared to controls (2257mg/L
versus 46 mg/L; p50.0001) (Hernandez-Diaz et al., 2009).
Similarly, DEP is present in some prescription medication
preparations of didanosine, omeprazole and theophylline and
mean urinary concentrations of MEP, the main DEP metab-
olite, were significantly higher in those taking the medica-
tions than in a reference population (Hernandez-Diaz et al.,
2009). Hence, some medications can be a source of high
exposure to some phthalates and thus raise concern about
potential human health risks resulting from these exposures.
In view of widespread human exposure and potential greater
exposure through some medications, the possibility that
phthalates could affect health is concerning. Therefore, we
conducted a systematic review of the literature to evaluate the
strength of the evidence concerning the potential reproductive
and developmental health effects of phthalates. For the
purposes of this review, we defined reproductive and
developmental toxicity as the ability of phthalates to
adversely affect reproductive health in women or the repro-
ductive capacity of experimental animals at any stage
throughout the life-span. Potential adverse effects of phthal-
ates on the risk of breast cancer or mammary gland
development were included in this review owing to the role
of estrogens and other hormones in mammary gland devel-
opment and pathophysiology of breast cancer.
Approach to systematic review
A Pubmed search was carried out to identify studies relevant
to the effect of phthalates on the female reproductive system.
Topics of interest included puberty, fertility, endometriosis,
polycystic ovarian syndrome (PCOS), pre-eclampsia or
eclampsia, spontaneous abortion and pregnancy outcomes.
The search terms used and the number of articles retrieved
were: phthalic acid or phthalates AND abortion spontaneous
OR miscarriage, 30 articles; phthalic acid AND endometri-
osis, 13 articles, phthalic acid OR phthalates AND fertility
OR infertility, 142 articles; phthalic acid AND obstetric labor,
premature OR infant, premature OR fetal development OR
preterm delivery OR birth weight, 154 articles; and phthalic
acid OR phthalates AND puberty OR puberty, delayed OR
puberty, precocious, 49 articles. Searches for articles on
phthalic acid OR phthalates AND polycystic ovarian syn-
drome, phthalic acid OR phthalates AND pre-eclampsia, and
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phthalic acid OR phthalates AND eclampsia each returned
one article which was not relevant to the focus of this review.
In total, 388 articles were initially retrieved. Of these,
duplicate papers (n¼ 35), reviews (n¼ 17), and unrelated
(n¼ 265) or inaccessible (n¼ 5) articles were excluded. The
abstracts of the remaining articles were read and studies
describing the effect of phthalates on the female reproductive
system in humans or animals were retained for further
assessment. Studies examining phthalates in combination
with other compounds or examining outcomes in areas other
than the reproductive system were excluded. Relevant studies
were also identified through a concurrent search on the effects
of phthalates in the male reproductive system as some studies
provided information about effects on the pregnant animals
despite focusing on males. Additional searches were carried
out as new topics such as breast cancer were identified.
Non-systematic searches, for example on follicle health, were
also conducted to explore the areas of interest. Finally,
bibliographies of all retained articles were searched for
additional relevant citations.
Epidemiological literature
Puberty
Seven studies were identified in which the effect of phthalate
exposure on the onset of puberty in girls was reported. In one
study of six girls, no effect of phthalate exposure during
infancy on puberty was reported (Rais-Bahrami et al., 2004).
However, as exposure was remote to the time of puberty
assessment and animal studies have shown that the effects of
phthalates are reversible (Alam et al., 2010; Boekelheide
et al., 2009; Oishi 1985; Saffarini et al., 2012), any potential
effect of phthalate exposure may have been missed. Other
studies of puberty in girls yielded conflicting results. Two
studies reported that increased phthalate concentrations were
correlated with premature thelarche (in one study,
96.5 134 ng/ml monomethyl phthalate (MMP) in cases
versus 26.4 30 ng/ml MMP in controls p¼ 0.005; in the
other, 68% of cases had high serum concentrations of
phthalates) (Chou et al., 2009; Colon et al., 2000).
However, the possibility that the samples in these studies
were inadvertently contaminated by environmental sources of
phthalates cannot be excluded, an issue that has been
discussed previously (McKee, 2004). Both studies had small
samples sizes with only 41 cases of premature thelarche in
one study (Colon et al., 2000) while 30 cases of premature
thelarche and 26 cases of central precocious puberty with 33
controls were described in the second study which was only
obtained as an abstract (Chou et al., 2009). In contrast, a study
with a larger sample size measured development in normal
girls twice a year and found that low-molecular-weight
phthalates, or phthalate diesters with short alkyl chains,
were non-significantly (p¼ 0.087) correlated with more rapid
breast development (Wolff et al., 2010). This study also
reported an association between exposure to the high-
molecular-weight phthalates and a significant decrease in
the development of pubic hair (p¼ 0.04) (Wolff et al., 2010).
Similarly, in another study involving 725 girls, no association
between phthalate exposure, as measured in urine, with breast
development was found; however, there was an association
with delayed pubic hair growth (mean age 11.4 years [11.1–
11.7] in the fourth quartile of exposure compared to 10.7
years [10.4–11.0] in the first) (Frederiksen et al., 2012).
As phthalates are considered anti-androgenic compounds,
delayed appearance of pubic hair is not unexpected. Similarly,
while phthalates are only weakly estrogenic, they may also be
able to affect breast development. However, assessment of
breast development may be confounded by increased body
weight and failure to distinguish between increased adiposity
and breast bud development, yielding misleading conclusions
about the onset of puberty (Walvoord, 2010).
Phthalates have also been investigated for an association
with precocious puberty. One case control study, available only
in English abstract form, observed higher levels of phthalates in
the serum of girls with precocious puberty (27.3% and 22.7% of
cases with DBP and DEHP compared to 4% and 3% of controls)
(Qiao et al., 2007). Unfortunately, phthalate exposure was
measured in serum and thus the potential for sample contam-
ination cannot be excluded. Furthermore, no association
between phthalates and precocious puberty was found in a
study of 28 case/control pairs when metabolites were measured
in urine (Lomenick et al., 2010). Additionally, one large cohort
study compared the concentrations of phthalate metabolites in
the urine of 725 healthy and 25 girls with precocious puberty
and reported no difference between the groups (Frederiksen
et al., 2012). Therefore, we conclude that the evidence does not
support an association between phthalate exposure and preco-
cious puberty.
Endometriosis
Endometriosis is an estrogen-dependent disease characterized
by the growth of endometrial epithelial and stromal cells
anywhere in the body outside the uterine cavity. The central
role of estrogens in the pathophysiology of endometriosis has
led several investigators to postulate a potential relationship
between phthalate exposure and endometriosis; however, the
results have been ambiguous. In one case-control study, with
35 cases and 24 controls, higher DEHP concentrations were
found in cases compared to controls (p¼ 0.0047) (Cobellis
et al., 2003). Another case-control study reported a non-
significant association between DEHP and endometriosis
(OR¼ 1.001 [1.000–1.002] p¼ 0.161) but found a significant
weak association between MEHP and endometriosis
(OR¼ 1.020 [1.003–1.038] p¼ 0.020) after analyzing 97
cases and 169 controls (Kim et al., 2011). In addition, higher
concentrations of DBP, BBP, DEHP and DnOP (p50.01)
were found in 49 women with endometriosis versus 38
infertile controls and 21 fertile controls and exposure to DBP,
BBP, DEHP and DnOP was correlated with the severity of
endometriosis (p50.01 for all) (Reddy et al., 2006a). Higher
concentrations of DBP, BBP, DEHP and DnOP in cases
compared to controls were also reported in a case-control
study with a larger sample size (85 cases and 135 controls)
(Reddy et al., 2006b). Taken together, the above studies
suggest that there is a weak association between phthalate
exposure and endometriosis. However, phthalates were
measured in plasma leading to the possibility of sample
contamination from plastics used to obtain or analyze the
samples, and thus provide potentially misleading results.
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Indeed, in one study, no correlation between DEHP and
MEHP concentrations was found, suggesting that higher
DEHP concentrations in plasma may be the result of sample
contamination (Cobellis et al., 2003). Methodological prob-
lems were also present in other studies. No association
between urinary phthalate concentrations and endometriosis
was found in another case-control study which grouped
endometriosis-free and endometriosis-stage 1 women together
as controls (80 women) while treating more advanced stages
of endometriosis as cases (57 women) (Itoh et al., 2009).
Other investigators, using measures of phthalate metabolites
in the urine, have also been unable to demonstrate significant
relationships between phthalate exposure and endometriosis
(Huang et al., 2010; Weuve et al., 2010). The concentrations
of the phthalate metabolites MBP and MEHP were non-
significantly higher (p50.1) in endometriosis cases (n¼ 28)
compared to controls in one study (Huang et al., 2010).
Similarly, a non-significant association between MBP and
endometriosis was found in another study (Weuve et al.,
2010). Furthermore, MEHP was significantly higher in
controls compared to cases (p¼ 0.03) in this cross-sectional
study involving 1221 women including 201 cases (Weuve
et al., 2010). However, case/control status was determined
by questionnaire and past diagnosis (Weuve et al., 2010).
Given that a definitive diagnosis of endometriosis requires
an invasive procedure (surgery) and histopathological con-
firmation results in significant delays in diagnosis, the
potential for misclassification error in these studies is high.
Hence, due to the poor reliability of studies in which exposure
was determined through the quantification of phthalates in
plasma and methodological difficulties, we suggest that the
available literature currently fails to support any association
between phthalate exposure and endometriosis.
Leiomyomas
Leiomyomas or fibroids are noncancerous tumors in the uterus
whose cause is unknown, but are thought to be tied to estrogen
and potentially progesterone exposure. Therefore, a possible
association between phthalate exposure and leiomyomas was
also investigated in two studies. However, while MEHP
exposure was higher in cases with leiomyomas compared to
controls (OR¼ 2.90 [1.05–7.97]; p¼ 0.04), other metabolites
(MEP, MBP, MBzP, MEOHP, MEHHP) were not significantly
different between cases and controls in one study (Huang et al.,
2010). In a second study, MBP was non-significantly higher in
cases and MEHP was non-significantly higher in controls
(OR¼ 1.56 [0.93–2.61] and OR¼ 0.63 [0.35–1.12], respect-
ively) (Weuve et al., 2010). Hence, the results are equivocal
and we conclude that they are insufficient to establish a
relationship between phthalate exposure and leiomyomas.
Time-to-pregnancy and pregnancy loss
Only one epidemiological study was found that examined a
potential association between phthalate exposure and female
fecundity. In a cohort study involving 6302 women, increased
time to pregnancy after probable occupational exposure to
phthalates was observed (OR¼ 2.16 [1.02–4.57]) (Burdorf
et al., 2011). While this study suggests that phthalate exposure
can negatively impact conception, we note that exposure to
phthalates was not directly quantified and thus consider this
weak evidence of a potential association.
The literature examining the relationship between early
and late pregnancy loss and phthalate exposure is also sparse.
One study used the data collected in a previous prospective
cohort study as well as stored urine samples to examine
possible associations between phthalate exposure (DEP,
DEHP, DBP, BBP) and subclinical early pregnancy loss as
well as clinical spontaneous abortions (Toft et al., 2012). High
MEHP exposure (third tertile) was associated with early
pregnancy loss when compared to low MEHP exposure
(first tertile) (OR¼ 2.87 [1.09–7.57]) (Toft et al., 2012).
Conversely, increased exposure to MEHP was protective for
late pregnancy loss (third to first tertile: OR¼ 0.25 [0.05–1.8],
second to first tertile: OR¼ 0.17 [0.03–0.95]) (Toft et al.,
2012). Although the authors suggested that an increased loss of
susceptible early pregnancies led to the decrease in spontan-
eous abortions later in pregnancy, they acknowledge that their
results could be due to chance (Toft et al., 2012). A second
study, obtained only in abstract form, reported an increased
risk for spontaneous abortions with increased exposure to
phthalates (Tabacova et al., 1999). Despite the paucity of
studies, we suggest that the association between phthalate
exposure and early pregnancy loss merits further study.
Pregnancy outcomes
We identified 12 studies examining potential relationships
between phthalate exposure during pregnancy and gestation
length and birth weight. In a cohort study of 283 women,
metabolites of DEHP in urine were associated with increased
gestational age (MEHP: OR¼ 2.0 [1.1–3.5], MEOHP:
OR¼ 2.2 [1.3–4.0], MEHHP: OR¼ 2.1 [1.3–3.7]) (Adibi
et al., 2009). Accordingly, exposure to DEHP was concluded
to be associated with a protective effect on preterm birth
(Adibi et al., 2009). Similarly, an association between low-
molecular-weight phthalates in urine and increased gesta-
tional age at birth (¼ 0.14 week [0.01–0.27 week]) was
found in a cohort of 382 pregnant women (Wolff et al., 2008).
When specific phthalates were examined, the association was
again with MEHP (¼ 0.15 weeks [0.02–0.29]) (Wolff et al.,
2008). On the other hand, the absence of MEHP in cord blood
was associated with increased gestational age (OR¼ 1.50
[1.013–2.21]) in a cross-sectional study involving 84 infants
(Latini et al., 2003). Likewise, MEHP in the urine was
associated with decreased gestational age (5.0 d shorter
[2.1–8.0 d], p¼ 0.001 between fourth and first quartiles) in
a cohort study involving 311 maternal infant dyads (Whyatt
et al., 2009). In this study, exposure to DEHP was quantified
by measuring metabolites in urine in addition to measuring
inhaled DEHP exposure using personal air sampling pumps
over a 2 d period (Whyatt et al., 2009). Interestingly, the levels
of DEHP in the air were not significantly correlated with
gestational age (Whyatt et al., 2009), suggesting that other
sources may be more important contributors to exposure.
We also note that contradictory results may arise from
exclusion of extremely premature infants from the study.
For example, a correlation between phthalate exposure and
increased gestational age was found when infants born at less
than 32 weeks of gestation were excluded (Wolff et al., 2008)
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whereas the opposite was found when infants born from
27 weeks of gestation were included (Latini et al., 2003). Two
studies included infants born at less than 37 weeks gestation
but their inclusion/exclusion criteria for extremely premature
infants was unclear (Adibi et al., 2009; Whyatt et al., 2009).
Other studies directly examined preterm birth as opposed
to gestational age. No significant association between preterm
birth and phthalate exposure was found in a cohort of 6302
women (Burdorf et al., 2011). However, exposure was not
directly measured in this study but was estimated through
estimates of occupational exposure only. On the other hand,
preterm birth was correlated with increased maternal expos-
ure to most phthalates measured as metabolites in urine
(MBP, mono-isobutyl phthalate (MiBP), mono-3-carboxypro-
pyl phthalate (MCPP), MEHP, MEHHP and MEOHP) in a
case-control study with 30 cases and 30 controls (Meeker
et al., 2009). When adjusted for dilution using creatinine, only
the concentration of MBP was significantly associated with
preterm birth (OR¼ 5.4 [1.5–19.3]) (Meeker et al., 2009).
These results suggest that phthalate exposure may be
associated with preterm birth and, therefore, that an effect
on gestational age may be observed in observational studies
depending on the inclusion criteria regarding premature
infants.
Several studies reported a decrease in infant size after
in utero phthalate exposure whereas other studies reported the
opposite and still others were unable to show any relationship
(Burdorf et al., 2011; Huang et al., 2009; Philippat et al., 2012;
Suzuki et al., 2010; Wolff et al., 2008; Zhang et al., 2009). For
example, Burdorf et al. (2011) suggested that occupational
exposure to phthalates was associated with low birth weight
(OR¼ 2.42 [1.10–5.34]). Similarly, after the measurement of
phthalate exposure in umbilical vein blood, maternal blood and
meconium in 88 cases and 113 controls, DBP and MEHP were
associated with low birth weight (DBP: OR¼ 3.54 [1.54–6.15],
p¼ 0.008; MEHP: OR¼ 2.05 [1.17–3.70], p¼ 0.05) whilst
DEP and DEHP were not significantly associated with birth
weight (Zhang et al., 2009). Two other studies directly
contradict these results and report an association between
phthalate exposure as measured using urinary biomarkers and
increased size at birth (Huang et al., 2009; Wolff et al., 2008). In
a cohort study of 65 children, increased birth weight and length
were associated with exposure to DBP, quantified as metab-
olites in urine (birth weight p¼ 0.031; length p¼ 0.018
between first and fourth quartiles) (Huang et al., 2009).
However, premature infants were included in this study,
potentially biasing results towards the null effect and thus the
association may be stronger than reported. In the second study,
an association between exposure to phthalates with low
molecular weights and increased head circumference (¼ 0.13
cm [0.01–0.24 cm] with increases in concentration) was found
(Wolff et al., 2008). Associations between MBzP, a metabolite
of BBP, and length (¼ 0.20 cm [0.00–0.40]) as well as with
MEP, a metabolite of DEP, and head circumference (¼ 0.12
cm [0.01–0.23]) were also reported (Wolff et al., 2008). Still,
other studies reported no association between the birth size and
phthalate exposure. In a cohort of 287 women, no association
was found with the birth weight, length or head circumference
after measuring phthalate exposure in urine (p40.14)
(Philippat et al., 2012). Additionally, no association was
found between urinary concentrations of phthalate metabolites
and any birth outcome measured in a cohort study of 149
women (Suzuki et al., 2010). In this study, the birth outcomes
measured included weight, length and head circumference
(Suzuki et al., 2010). Taken together, on a weight-of-evidence
basis, studies in which exposure was assessed through urinary
metabolites, extremely premature infants were excluded, and
effects on birth weight were corroborated by complementary
measures, suggest only a weak association between phthalate
exposure and premature birth.
Breast cancer
A possible relationship between phthalate exposure and
breast cancer has been investigated in several studies yielding
mixed results. One large case-control study with 233 cases
and 221 controls reported increased mean concentrations of
MEP but decreased mean concentrations of MBP, MCPP and
MEOHP in the urine of women with breast cancer compared
to controls (Lopez-Carrillo et al., 2010). The odds ratios, after
correction for age, age of menarche, parity and menopausal
status, showed a protective effect of MBzP and MCPP
exposure (MBzP: OR¼ 0.46 [0.27–0.79], p¼ 0.008; MCPP:
OR¼ 0.44 [0.24–0.80], p¼ 0.007) (Lopez-Carrillo et al.,
2010). On the other hand, increased urinary concentrations of
MEP and mono-2-ethyl-5-carboxypentyl phthalate (MECPP),
a metabolite of DEHP, were significantly associated with
increased breast cancer risk (MEP: OR¼ 2.20 [1.33–3.63],
p¼ 0.003]; MECPP: OR¼ 1.68 [1.01–2.78], p¼ 0.047)
(Lopez-Carrillo et al., 2010). The odds ratio for MECPP
was only borderline significant and may have been due to
chance, especially as the other metabolites of DEHP were not
significantly different between cases and controls (Lopez-
Carrillo et al., 2010). A second case-control study examined
occupational exposure to endocrine disrupting compounds
including BBP in 261 cases and 753 controls and found
no association with breast cancer (Aschengrau et al., 1998).
However, a limitation of this study is its failure to directly
quantify exposure, instead relying only on estimates from
potential occupational exposure to BBP. Based on these two
studies, exposure to phthalates is not thought to be associated
with an increased risk of breast cancer and may even be
protective.
However, the lack of association between phthalate
exposure and breast cancer risk was unexpected as phthalates
are thought to have estrogenic properties and thus play a role
in the pathobiology of breast cancer. For example, BBP and
DBP both increased transcription of an estrogen-regulated
gene in breast cancer cells after treatment with a combination
of estradiol and phthalate (Jobling et al., 1995). Furthermore,
these cells proliferated in response to DBP and BBP alone,
although cell growth was less than after treatment with
estradiol (Jobling et al., 1995). These results suggest that
phthalates are weakly estrogenic and may act as partial
agonists (Jobling et al., 1995). In a second study, BBP was
more potent than DEP after the estrogenic activity of the main
phthalates was compared (Harris et al., 1997). Furthermore,
BBP but not DEP increased the proliferation of human breast
cells in vitro (Harris et al., 1997). Still, the phthalates with
estrogenic properties were much less potent than estradiol
(Harris et al., 1997). The results from these in vitro studies
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are difficult to reconcile with the protective effect seen
by Lopez-Carrillo and colleagues. One hypothesis is that the
phthalates may compete with estradiol for the estrogen
receptor, decreasing the effect of estrogen on breast cancer
(Jobling et al., 1995). However, as BBP and DBP added to
the effect of estradiol in culture, this is unlikely. Moreover,
BBP and other phthalates were more potent estrogenic
compounds (although still weak) than DEP (Harris et al.,
1997). In summary, we conclude that the current literature is
insufficient to support a role, if any, of phthalate exposure
in the development or progression of breast cancer.
Animal studies
While epidemiological studies are able to uncover potential
associations between environmental contaminant exposure
and adverse health outcomes (as summarized in Table 1), they
alone cannot establish causal links. Animal experiments are
important because they allow for controlled exposure to
known quantities of test chemicals in genetically similar or
identical animals, and thus allow for mechanistic insight that
cannot be achieved through epidemiological studies. Hence,
animal studies are essential to understand potential causal
links between phthalate exposure and adverse health out-
comes and provide insight into the mode of action as well as
dose–response characteristics. Therefore, the effects of
phthalate exposure on the reproductive health of experimental
animals were evaluated. There was a paucity of studies for
many of the phthalate diesters, whereas multiple studies were
found for the more common phthalates. For each phthalate the
lowest observed adverse effect level (LOAEL), no observed
adverse effect level (NOAEL) and main adverse outcomes
reported are summarized in Table 2.
Dimethyl phthalate
Prior studies have established that phthalate potency is related
to the length of alkyl chains with the most potent phthalates
having chain lengths of 4–6 carbon atoms (Gray, Jr. et al.,
2000; Heindel et al., 1989). Dimethyl phthalate (DMP) is the
phthalate diester with the shortest alkyl chain length and is
therefore thought to be less toxic than other phthalates. In the
only study found, DMP exposure had no effect on pregnancy
at doses up to 2 ml/kg when administered during early
gestation to Sprague–Dawley rats through intraperitoneal (ip)
injection (Peters & Cook, 1973). Although ip injection
bypasses first pass metabolism of the DMP by the liver, the
absence of any adverse effects is reassuring.
Diethyl phthalate
Three studies examined the effect of diethyl phthalate (DEP)
exposure on the female reproductive system. Two of these
studies focused exclusively on pregnancy outcomes whereas
one administered a mixture of contaminants including DEP
to mice (Hayashi et al., 2010). In this study, DEP made up
0.7 ppm of the mixture, two mice failed to become pregnant
and delivery in the other mice was delayed (Hayashi et al.,
2010). Unfortunately, the results of this study cannot be
attributed solely to DEP, and thus were not considered further
in this review.
Dietary exposure to DEP at doses of 0.25–2.5% (approxi-
mately 340–3640 mg/kg/d) had no effect on the litter size, the
number of pups born and pup weight in Swiss CD-1 mice;
however, the number of pups per litter was decreased in
the next generation (Anonymous, 1997b), suggesting a
transgenerational effect of continuous exposure. In another
study, no change in estrous cycle characteristics was found in
Sprague–Dawley rats administered 600–15 000 ppm DEP in
diet over two generations (approximately 40–1375 mg/kg/d);
however, vaginal opening was delayed at 15 000 ppm in the
second generation (Fujii et al., 2005). Furthermore, the
duration of pregnancy was shortened and the weights of the
pups decreased (Fujii et al., 2005). Additionally, pinna
detachment and eye opening in the pups was delayed at
15 000 ppm (1000–1375 mg/kg/d) even though there was no
effect on the development of other reflexes (Fujii et al., 2005).
Taken together, these studies suggest that DEP may nega-
tively affect the female reproductive system (pregnancy and
puberty after in utero exposure) at high doses administered
throughout the lives of the animals. The results also indicate
that the most sensitive period for exposure is during gestation
and that potential transgenerational effects of DEP can occur.
However, we also note that the lowest doses used in these
studies are approximately 100 times greater than human
exposure and effects were only noted at the highest concen-
trations used.
Dipropyl phthalate
Only two studies were found that examined the effects
of dipropyl phthalate (DPrP) on pregnancy. In one study, adult
female Swiss CD-1 mice at the highest dose (5% in diet or
approximately 8600 mg/kg/d administered before and during
breeding) were infertile (Heindel et al., 1989). Additionally,
there were fewer pups per litter in the 2.5% DPrP in the
diet (4100 mg/kg/d) treatment group (Heindel et al., 1989).
However, female fertility was unaffected at 1.25% in diet
(1900 mg/kg/d) (Heindel et al., 1989). In contrast, in utero
exposure to DPrP (gestational day (GD) 6-GD20) had no
effect on pregnancy in Sprague–Dawley rats at all doses
administered by gavage (up to 1500 mg/kg/d) although
pup weight was decreased starting in the 1000 mg/kg/d
treatment group (Saillenfait et al., 2011b). Impaired develop-
ment of the pups, supernumerary ribs, and fewer ossification
centers in the paws was observed after exposure to 1000 and
1500 mg/kg/d (Saillenfait et al., 2011b). These studies suggest
a negative effect of DPrP on the female reproductive system
and a possible teratogenic role at high doses.
Dibutyl phthalate
We found 20 studies that examined the effect of dibutyl
phthalate (DBP), a phthalate diester with four carbon alkyl
chains, on the female reproductive system. The effect of DBP
exposure on sexual maturation, fertility and pregnancy
outcomes, development of the female reproductive tract, and
mammary gland development and tumors has been studied.
Sexual maturation
In total, six studies examining sexual maturity, either through
vaginal opening or the estrous cycle, were found. Four of
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these studies did not demonstrate any evidence of a DBP-
induced change in the onset of sexual maturity as measured
by the day of vaginal opening in Long–Evans, Wistar or
Sprague–Dawley rats (Gray, Jr. et al., 2006; Guerra et al.,
2010; Mylchreest et al., 1998, 2000). The highest dose used in
these studies was 750 mg/kg/d (Mylchreest et al., 1998), while
the lowest dose used was 0.5 mg/kg/d (Mylchreest et al.,
2000). The exposure periods in these studies included
postnatal day (PND) 21 to sacrifice, GD12-PND21, GD3-
PND20 and GD12-21 (Gray, Jr. et al., 2006; Guerra et al.,
2010; Mylchreest et al., 1998, 2000). Therefore, these studies
suggest no effect of DBP on vaginal opening at either high
or low doses when exposure occurs at any time (during
gestation, nursing or after weaning). However, two studies
reported a trend for delayed onset of vaginal opening in
Sprague–Dawley rats exposed to 10 000 ppm in diet GD15-
PND21 (Lee et al., 2004) and significantly delayed the onset
of vaginal opening in Long–Evans rats exposed to 12 or
50 mg/kg/d in utero and after birth until sexual maturation,
respectively (Salazar et al., 2004). Additionally, first estrus
was delayed at 50 mg/kg/d (Salazar et al., 2004). However, the
litter was not the statistical unit in one study (Salazar et al.,
2004), meaning that similarities between animals from the
same litter could affect the conclusions. Therefore, the results
may not be an accurate indication of the effects of DBP at a
low dose. The doses of DBP used in these conflicting studies
covered a similar range and mainly utilized the same route of
administration (gavage). While different strains of rats were
used, strain differences do not appear to be responsible for
the inconsistent results. Despite the two studies reporting
an effect, we propose that overall, the evidence suggests
that DBP does not affect sexual maturation and the onset of
sexual maturity, results that are remarkably harmonious
with those in the epidemiological literature (Frederiksen
et al., 2012; Wolff et al., 2010).
Fertility and pregnancy loss
DBP exposure has been shown to decrease maternal weight
gain, fetal weight and food consumption as well as increase
the number of resorptions, and pre- and post-implantation
losses in animal studies. Adverse effects on pregnancy and
maternal health became apparent at doses of DBP or MBP
administered by gavage during gestation from 500 mg/kg/d
and up, including a reduction in maternal weight gain and in
fetal weight in Wistar, Long–Evans and Sprague–Dawley rats
(Ema & Miyawaki, 2001a,b; Ema et al., 1995, 1996c, 2000;
Gray, Jr. et al., 2006; Zhang et al., 2004). While some studies
in Wistar rats reported effects as mild as changes in maternal
food consumption and weight gain, or in the weight of the
pups (Ema et al., 1996c, 2000), other studies reported
a decrease in the number of live pups at similar doses
(500 mg/kg/d by gavage or 1% in diet) in Long–Evans and
Sprague–Dawley rats (Gray, Jr. et al., 2006; Wine et al.,
1997). Increases in pregnancy loss, including increases in
resorptions and the number of dead fetuses, at doses
of 500 mg/kg/d or higher have also been reported in Wistar
and Long–Evans rats (Ema et al., 1996c, 2000; Gray, Jr. et al.,
2006). Additionally, more female Wistar rats were unable
to become pregnant when exposed to 1250 or 1500 mg/kg/d
compared to controls (Ema et al., 2000). Interestingly, a
decrease in the maternal weight and an increase in pregnancy
loss was reported at a dose of 50 mg/kg/d in Long–Evans rats
(Salazar et al., 2004).
Other groups, however, have reported no effect on
pregnancy in rats after doses of 500 mg/kg/d (Barlow &
Foster, 2003; Carruthers & Foster, 2005; Ema et al., 1993a;
Ema 2002; Fisher et al., 2003; Jiang et al., 2007; Mylchreest
et al., 2000, 1998; Struve et al., 2009). One study examining a
lower dose of DBP (100 mg/kg/d by gavage GD12-PND21)
reported no effects on pregnancy outcomes including mater-
nal weight, the number of implantation sites, serum proges-
terone and fertility of the female Wistar rats exposed during
gestation (Guerra et al., 2010). Overall, the studies which
examined both the health of the pregnant dam and the
reproductive health of the male pups generally found that the
doses needed to affect the dam were higher than the doses
that affected the male pups (Barlow & Foster, 2003;
Carruthers & Foster, 2005; Ema & Miyawaki, 2001a; Fisher
et al., 2003; Jiang et al., 2007; Lee et al., 2004; Mylchreest
et al., 1998, 2000; Salazar et al., 2004; Struve et al., 2009;
Zhang et al., 2004).
The mode of DBP action has been poorly defined;
however, decreased progesterone was observed in pregnant
Wistar rats treated with 1500 mg/kg/d DBP although there
was no change in estradiol (Ema et al., 2000). Similarly,
a decrease in serum progesterone in Long–Evans rats was
reported after exposure to 500 mg/kg/d (Gray, Jr. et al., 2006).
Furthermore, in this study, DBP decreased progesterone
and increased estradiol production from ovaries in vitro
(Gray, Jr. et al., 2006). These studies suggest that the effects
of DBP may occur through changes in the circulating
concentration of the hormones responsible for maintaining
pregnancy.
Female reproductive tract
DBP treatment has been reported to have no effect on estrous
cycle characteristics in rats at doses up to 1000 mg/kg/d by
gavage and 1% DBP in diet even if exposure occurred during
gestation (Gray, Jr. et al., 2006; Guerra et al., 2010; Wine
et al., 1997). However, a non-significant increase in estrous
cycle irregularity after exposure to 2000 and 10 000 ppm DBP
in diet GD15-PND21 has also been observed (Lee et al.,
2004). Still, other outcomes including ovarian histology in
female fetuses, anogenital distance (AGD) in female pups,
number of nipples, ovary and uterine weight and histology,
number of corpora lutea and follicles at different develop-
mental stages, serum follicle stimulating hormone (FSH),
luteinizing hormone (LH), progesterone concentrations and
mating behavior in Wistar rats were all unaffected after in
utero and lactational exposure to 100 mg/kg/d of DBP (Guerra
et al., 2010). Thus, the absence of an adverse effect on
complementary outcome measures leads us to conclude that
the female reproductive tract function is relatively insensitive
to potential toxic effects of DBP exposure.
Mammary gland development
Only one study that examined the histology of the mammary
glands after exposure to DBP was found. In this study,
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hypoplasia of the mammary glands was observed in Sprague–
Dawley rats after in utero exposure to doses as low as 20 ppm
DBP in diet (Lee et al., 2004). These data suggest a potential
anti-estrogenic effect of DBP exposure on mammary gland
development. Further, the epidemiological studies to date do
not support a role for DBP in the development of breast
cancer and are consistent with the results of the present
review.
The lowest NOAEL reported for female rats was 50 mg/kg/
d (Zhang et al., 2004). Other studies in rats reported NOAELs
of 250 mg/kg/d (Ema 2002; Ema & Miyawaki, 2001a,b;
Ema et al., 1995, 2000; Gray, Jr. et al., 2006; Mylchreest
et al., 1998). On the other hand, studies have also reported
LOAELs of 20 ppm in diet and 50 mg/kg/d by gavage
(Lee et al., 2004; Salazar et al., 2004). Overall, DBP is able
to adversely affect the health of pups exposed in utero as well
as the reproductive health of female animals exposed as
adults.
Di-isobutyl phthalate
The majority of the studies found no effect of di-isobutyl
phthalate (DiBP) exposure on pregnancy in Wistar and
Sprague–Dawley rats at doses up to 625 mg/kg/d (Boberg
et al., 2008; Borch et al., 2006; Saillenfait et al., 2008b).
However, decreased maternal and fetal weights at 500 mg/kg/
d administered orally during gestation as well as increased
resorptions and fetal deaths at 750 mg/kg/d or higher doses
were seen in a separate study conducted in Sprague–Dawley
rats (Saillenfait et al., 2006). Interestingly, increased AGD in
female Wistar rat pups was found in two studies administering
in utero doses of 600 mg/kg/d by gavage (Boberg et al.,
2008; Borch et al., 2006). Additionally, the expression of
aromatase in the ovaries was increased after oral exposure
to 600 mg/kg/d (Boberg et al., 2008). Currently, a NOAEL of
250 mg/kg/d DIBP is suggested based on maternal toxicity
and the weights of pups (Saillenfait et al., 2006).
Butylbenzyl phthalate
Like DBP, one metabolite of butylbenzyl phthalate (BBP) is
MBP; however, the effects of BBP are less well documented.
We found and reviewed 14 articles examining the effects of
BBP on sexual maturation, fertility and pregnancy, and
mammary tumors.
Sexual maturation
The effect of BBP on sexual maturation in female animals
is unclear, with several studies providing divergent findings.
A 2 d delay in vaginal opening was reported in Sprague–
Dawley rats exposed orally to 500 mg/kg/d BBP in utero
(Moral et al., 2011). On the other hand, a low dose of BBP
(183mg/kg), administered in drinking water, was reported to
advance vaginal opening by 1 d in AP rats exposed during
gestation and nursing (Ashby et al., 1997). It is important to
note that these studies did not consider litter effects, meaning
their results may be affected by similarities between animals
from the same litter. Other studies reported no change in
the onset of sexual maturity using oral doses from 20 to
500 mg/kg/d in Sprague–Dawley rats (Aso et al., 2005;
Nagao et al., 2000). The reasons for the contradictory results
in these studies are difficult to resolve. In one study, the
advance in vaginal opening was the only significant effect
observed and the authors suggest that it was due to the
increased weights of the pups (Ashby et al., 1997). However,
because opposing effects have been reported at high and low
doses, more research on the effect of low doses of BBP on
puberty is needed to rule out a potential biphasic effect.
Fertility and pregnancy
Exposure to BBP during pregnancy induced decreased body
weight gain, decreased food consumption, increased resorp-
tions, an increased number of dead fetuses, decreased weight
of live fetuses and increased the incidence of external,
internal and skeletal malformations in rats (Ema & Miyawaki
2002; Ema et al., 1993b, 1996a,b, 1998, 1999, 2003; Piersma
et al., 2000; Uriu-Adams et al., 2001). The effects of BBP as
a teratogen in Wistar rats varied depending on when the
exposure occurred. Internal and skeletal malformations
occurred when oral exposure was provided from GD 7–9;
external and skeletal malformations occurred when exposure
was from GD 13–15; and relatively few malformations
occurred when exposure occurred between GD 10–12 (Ema
et al., 1993b, 1996a). Similarly, an increase in pre-implanta-
tion loss was found when exposure began on GD0 (Ema et al.,
1993b; Ema et al., 1998). Further, decreased ovarian weights
were found in 500 mg/kg/d treated Sprague–Dawley rats
(Nagao et al., 2000). BBP exposure (200 mg/kg/d orally) also
decreased uterine weights in treated Sprague–Dawley rats
(Aso et al., 2005).
Based on decreased uterine weights and decreased levels
of progesterone, it was suggested that decidualization in
pregnant rats dosed with BBP was reduced due to lower
serum concentrations of progesterone (Ema et al., 1994,
1998). Other hypotheses including changes in metabolism of
zinc as a result of BBP exposure have been postulated to
explain these observations; however, no real changes in the
absorption or distribution of zinc have been documented
(Uriu-Adams et al., 2001). On the other hand, a study
examining the viability of embryos treated in vitro with MBzP
found that embryo viability decreased at doses of 3 mM in rats
and 5 mM in mice (Saillenfait et al., 2003). This evidence
suggests that the adverse effects of BBP exposure on
pregnancy outcomes may, in part, result from the direct
effects of this metabolite on the embryo.
Mammary tumors
One study examined the effect of BBP on mammary gland
morphology in Sprague–Dawley rats and reported increases
in the number of terminal end buds, alveolar buds and
terminal ducts after exposure to 500 mg/kg/d BBP in utero
(Moral et al., 2011). Changes in proliferating cells were also
seen and the authors suggested that these effects increase the
susceptibility to breast cancer (Moral et al., 2011). However,
these results directly contradict an epidemiological study
in humans which reported a negative association between
concentrations of MBzP (a metabolite of BBP) in
urine and the incidence of breast cancer and a second
study which found no association between occupational
exposure to BBP and breast cancer (Aschengrau et al.,
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1998; Lopez-Carrillo et al., 2010). Thus, although the
literature is limited, we suggest that there is insufficient
evidence to either support or disprove a potential role of BBP
exposure in the pathophysiology of breast cancer.
Based on these studies, we conclude that BBP has the
ability to affect both the mature and developing female
reproductive system as well as pregnancy at high doses.
We note that one study examining doses of BBP relevant to
human exposure found no effect except for advanced vaginal
opening which was not believed to be a result of BBP. Thus,
BBP is thought to be a reproductive and developmental
toxicant only at high concentrations. The lowest NOAEL
reported for effects on pregnancy was 250 mg/kg/d (Ema
et al., 1998). On the other hand, 250 mg/kg/d caused a
decrease in maternal weight gain and food consumption
in other studies (Ema et al., 1996a,b). In general, we suggest
a NOAEL of 250 mg/kg/d, a dose that is much higher than
human exposure.
Di-pentyl phthalate (DPP)
Only two studies were identified in our search of the literature
that examined the effects of di-pentyl phthalate (DPP) on the
female reproductive system (Hannas et al., 2011; Heindel
et al., 1989). Fetal mortality was increased after oral exposure
of the pregnant Sprague–Dawley rats to 1200 mg/kg/d
(Hannas et al., 2011) and the number of litters and pups
decreased in Swiss CD-1 mice exposed to 0.5% DPP in diet
(760 mg/kg/d) before and during pregnancy (Heindel et al.,
1989). Female mice were infertile after exposure to 1.25%
DPP or greater in diet (2160 mg/kg/d) (Heindel et al., 1989).
Therefore, we conclude that DPP is a reproductive toxicant
at high concentrations.
Di-n-hexyl phthalate
In our search, three studies were identified that examined the
effects of di-n-hexyl phthalate (DnHP) exposure in female
animals. One study reported infertility in Swiss CD-1 mice
after exposure to 1.2% DnHP in the diet (1670 mg/kg/d) as
well as a decreased number of litters with fewer live pups
per litter at 0.3% (380 mg/kg/d) when exposure occurred
continuously over two generations (Anonymous, 1997a). In
the other two studies, oral DnHP exposure at concentrations
of 625 mg/kg/d and more during pregnancy increased post-
implantation losses, resorptions, and decreased the number
and weight of pups in Sprague–Dawley rats (Saillenfait et al.,
2009a,b). Based on these studies, we suggest that DnHP is a
reproductive toxicant at high concentrations.
Di-cyclohexyl phthalate
While di-cyclohexyl phthalate (DcHP) is thought to be less
potent than other phthalates due to the different configuration
of its alkyl groups (Saillenfait et al., 2009a), prolonged
estrous cycle length was found in Sprague–Dawley rats
exposed to 6000 ppm DcHP in diet (Hoshino et al., 2005).
Regardless, there was no effect of DcHP exposure on fertility
or pregnancy in this study and pup viability, development and
reflexes were also unaffected even in the pups of animals
exposed in utero and throughout their lifespan (Hoshino et al.,
2005). Similarly, a second study reported no changes in the
number of implantations or viable fetuses in Sprague–Dawley
rats after oral exposure GD6-20 to 750 mg/kg/d DcHP
(Saillenfait et al., 2009a). On the other hand, decreases in
pup weights were reported at 500 mg/kg/d (Saillenfait et al.,
2009a; Yamasaki et al., 2009). Additionally, a decrease in the
survival of pups to PND4 was seen after Sprague–Dawley rats
were exposed to 500 mg/kg/d during gestation (Yamasaki
et al., 2009). Thus, we suggest that these studies provide
evidence that DcHP in high concentrations is a reproductive
and developmental toxicant.
Di-(2-ethylhexyl) phthalate
Di-(2-ethylhexyl) phthalate (DEHP) has been relatively more
thoroughly researched than the other phthalates as shown by
the presence of 28 articles in the literature in which the impact
of DEHP on female reproductive health was investigated.
These studies describe the effects of DEHP on sexual
maturation, fertility and pregnancy loss, and changes to
female reproductive tract structure.
Sexual maturation
The effect of DEHP exposure on sexual maturation is unclear.
A non-significant trend for delayed first estrus and earlier
vaginal opening at oral doses from 375 to 1500 mg/kg/d has
been described in Sprague–Dawley rats exposed during
gestation (Moore et al., 2001). Both vaginal opening and
the time of first estrus were delayed starting at an oral dose
of 15 mg/kg/d in Wistar rats (Grande et al., 2006). However,
in another study using Wistar–Imamichi rats, both markers of
sexual maturation occurred earlier after exposure through
inhalation to approximately 1 and 5 mg/kg/d from PND22 to
PND84 (Ma et al., 2006). Interestingly, a third study reported
delayed vaginal opening in C57/Bl6 mice after oral exposure
to higher doses of DEHP (500 or 1000 mg/kg/d) in utero
(Moyer & Hixon, 2012). These conflicting results cannot be
explained by a difference in doses as these studies used
overlapping dose ranges, and found opposite effects at
relatively similar doses. Another possible explanation for
the inconsistent results is the length of exposure or the method
of administration, which varied between these studies. In one
study, oral exposure continued until weaning (Grande et al.,
2006), in the second, rats were exposed through inhalation
after weaning (Ma et al., 2006), and in the third, mice were
orally exposed only during gestation (Moyer & Hixon, 2012).
In summary, these animal studies suggest that DEHP at high
concentrations may be able to delay puberty. However, the
effect of low concentrations of DEHP is less clear, although it
may advance the onset of puberty.
Fertility and pregnancy loss
Several studies were found that revealed no effect of DEHP
exposure on pregnancy based on maternal weight and food
consumption, litter size and pup weights in mice and rats
(Anonymous, 1997d; Grande et al., 2006; Gray, Jr. et al.,
2009). In these studies, the doses used ranged from 0.05% in
the diet to 405 mg/kg/d orally (Anonymous, 1997d; Grande
et al., 2006; Gray, Jr. et al., 2009). Interestingly, Wistar rat
pup weights were increased at doses less than 5 mg/kg/d
(Grande et al., 2006). Also of interest, one study reported
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increased litter sizes after administering oral doses of 1000 mg/
kg/d to female mice (Moyer & Hixon, 2012). Other studies
using high doses of DEHP found negative effects on pregnancy.
Maternal weight and food consumption, as well as pup weight,
number of pups born and the rate of post-implantation loss were
variably affected at oral doses from 500 to 1500 mg/kg/d as well
as 10 ml/kg/d and 1% in diet in mice and rats (Anonymous,
1997c; Dalsenter et al., 2006; Jarfelt et al., 2005; Moore et al.,
2001; Peters et al., 1997; Pocar et al., 2012; Shirota et al., 2005;
Tomita et al., 1982; Tyl et al., 1988). One study reported a 100%
pregnancy loss rate after exposure to 500 mg/kg/d DEHP in
C3H/N mice (Schmidt et al., 2012). Decreased pup weight
in CD-1 mice was also found at a relatively low dose of 5 mg/kg/
d in diet, although resorptions did not increase until 500 mg/kg/
d (Pocar et al., 2012). While this study did not correct for a
possible litter effect, it suggests that adverse effects may also
occur at lower doses. Interestingly, the effects of DEHP
exposure on pregnancy in PPARa knockout mice as well as in
wild-type mice were similar at high doses in both groups of
mice (Peters et al., 1997). PPARa is thought to be at least
partially responsible for toxicity in rodents, particularly in the
liver. However, the human PPARa has lower affinity for
phthalates and is expressed at a lower level (Ito & Nakajima,
2008; Rusyn & Corton, 2011). As a result, the consequences of
phthalate exposure in rats may be due to mechanisms that are
not applicable in humans. However, as Peters et al. show, there
may be PPARa-independent pathways leading to reproductive
toxicity (Ito & Nakajima, 2008; Peters et al., 1997). Therefore,
the effects of DEHP in rats and mice may be biologically
relevant to humans despite the lesser importance of the PPARa
pathway in humans.
In Crj:CD-1 mice exposed to 0.01%, 0.03% and 0.09%
DEHP in the diet, one failure to become pregnant occurred in
both the 0.01% and 0.03% DEHP dose groups and pregnancy
loss was observed in one dam of the 0.03% treatment group
(Tanaka, 2002). At 0.09% DEHP in the diet, the survival
of the mice and the pups was significantly reduced (Tanaka,
2002). In the crossover mating trials, failures to become
pregnant occurred in both male-treated/female-control and
female-treated/male-control groups, suggesting that both
male and female fertilities are affected by DEHP exposure
(Tanaka, 2003). Although DEHP exposure negatively affected
fertility, the number of adverse events was small. Still, in a
separate study, failure to become pregnant occurred in some
Sprague–Dawley rats after oral exposure to 3000 mg/kg/d
(Takai et al., 2009).
A recent study revealed that after in utero exposure to 0.05
and 5 mg/kg/d DEHP in diet, the oocytes of treated rats
were less likely to mature and were less able to form a viable
zygote (Pocar et al., 2012). Similarly, an in vitro study has
demonstrated decreased mouse oocyte survival, possibly as a
result of oxidative stress after treatment with 250 mM MEHP
(Bonilla & Del, 2010). Furthermore, two studies have reported
impaired maturation of MEHP-treated oocytes (bovine and
mouse) in vitro (Anas et al., 2003; Dalman et al., 2008).
Likewise, growth of mouse follicles treated with 2.77 mM
DEHP, 0.34 mM MEHP or higher doses was decreased in vitro
(Gupta et al., 2010). Similarly, two recent studies treated mouse
follicle with DEHP and MEHP and reported decreased follicle
growth after doses from 0.1 to 100mg/ml MEHP and 1 to
100 mg/ml DEHP (Wang et al., 2012a,b). In these studies,
oxidative stress was increased as a result of treatment while
expression and activity of antioxidant enzymes were inhibited.
Interestingly, the enzyme affected by DEHP treatment, super-
oxide dismutase 1, was not the enzyme affected by MEHP,
glutathione peroxidase (Wang et al., 2012a,b). Furthermore,
co-treatment with an antioxidant (N-acetyl cysteine) rescued
follicle growth (Wang et al., 2012a,b). These results indicate an
adverse effect of both MEHP and DEHP on follicle growth
through reactive oxygen species. On the other hand, a second
in vitro study reported no changes in the development of mouse
follicles exposed to 200mM MEHP in culture (Lenie & Smitz,
2009). Still, another recent study reported decreased numbers
of primordial follicles as well as increases in the numbers of
primary, secondary and antral follicles after oral exposure to
1000 mg/kg/d DEHP, which the authors suggest indicated
increased recruitment of follicles and therefore a shorted
reproductive lifespan with earlier entry into ovarian failure
(Moyer & Hixon, 2012). Interestingly, in this study, the
animals’ concentrations of estradiol were decreased compared
to controls later in life, possibly supporting the authors’ idea of
earlier ovarian failure (Moyer & Hixon, 2012).
Other in vitro studies have also investigated changes in
steroidogenesis as a possible mode of action. One study
examined Fischer 344 rat granulosa cells treated with 100 mM
MEHP in vitro and reported decreases in progesterone as a
result of decreased cAMP response to FSH (Treinen et al.,
1990). While this study corroborates the idea that DEHP may
be able to negatively affect the production of progesterone,
other in vitro studies have found contradictory results. In one
study, progesterone production was increased in KK-1
granulosa tumor cells treated with 100 mM MEHP, although
there was no change in cAMP (Gunnarsson et al., 2008).
In another, progesterone and testosterone production were
increased in mouse follicles after treatment with 200 mM
MEHP (Lenie & Smitz, 2009). These results are at odds with
the idea that negative effects on reproduction are caused by
decreases in the circulating concentrations of progesterone.
Interestingly, both studies that reported increases in proges-
terone were conducted in mice while the study reporting
a decrease was conducted in rats. Thus, the opposing results
could be due to species differences. In vitro studies have
also examined changes in estradiol production. In Fischer 344
rat granulosa cells, estradiol was decreased after treatment
with 50 mM MEHP (Lovekamp-Swan et al., 2003). Decreases
in the expression of aromatase as a result of PPARg
activation, and increases in 17b-HSD expression as a result
of PPARa activation were thought to be responsible for the
change in steroidogenesis (Lovekamp-Swan et al., 2003).
Other studies have partially corroborated these hypotheses.
One reported a relative increase in estrone production and a
decrease in estradiol production from mouse follicles treated
with 200mM MEHP (Lenie & Smitz, 2009). Other studies
have reported decreases in estradiol combined with decreased
aromatase expression after exposure to 50 or 100 mM MEHP
(Davis et al., 1994b; Lovekamp & Davis, 2001). Overall,
these studies show that estradiol production can be affected by
MEHP treatment in vitro.
Studies conducted in vivo have also examined the effects
of DEHP on steroidogenesis. However, the results of these
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studies are mixed. One study found that serum estradiol and
progesterone concentrations were unaffected by exposure
to maximum oral doses of 405 and 2500 mg/kg/d DEHP in
Wistar rats and marmosets, respectively (Grande et al., 2007;
Tomonari et al., 2006). In contrast, circulating concentrations
of estrogen were decreased, FSH was increased and surges in
progesterone and LH were suppressed in adult Sprague–
Dawley rats at 2000 mg/kg/d, a dose that also prevented
ovulation (Davis et al., 1994a). Furthermore, estradiol and
progesterone concentrations were decreased in immature
Sprague–Dawley rats treated orally with 500 mg/kg/d DEHP,
potentially the result of decreased transport of cholesterol
across cell membranes (Svechnikova et al., 2007).
Additionally, Sprague–Dawley rats treated with 1400 mg/kg
DEHP twice a week had lower serum concentrations of
estradiol and FSH, as well as lower levels of FSH and LH in the
pituitary (Hirosawa et al., 2006). This study also examined
protein expression in the pituitary and concluded that secretion
of LH and FSH could be changed by DEHP treatment
(Hirosawa et al., 2006). On the other hand, increased levels
of estradiol and increased expression of aromatase in the
ovaries after low doses administered by inhalation (around
1 mg/kg/d) have also been reported (Ma et al., 2006). Similarly,
increases in estradiol and FSH as well as decreases in LH were
reported in mice after oral exposure to 1000 mg/kg/d (Moyer &
Hixon, 2012). Finally, one study reported increases in estradiol
and testosterone production from ovaries taken from mice
treated with 1500 mg/kg/d DEHP and cultured during the
diestrus stage of the estrous cycle (Laskey & Berman, 1993).
Taken together, these data suggest that DEHP can adversely
affect the ovarian function and steroidogenesis although the
mechanisms have yet to be defined.
Female reproductive tract
The impact of DEHP on female reproductive health in the
non-pregnant animal has been studied with equivocal results.
Two studies found no effect of DEHP on female reproductive
health in Wistar and albino rats when administered through
inhalation and intraperitoneal injections, respectively
(Klimisch et al., 1992; Seth et al., 1976), whereas three
studies have shown that DEHP exposure increased estrous
cycle length and induced irregular estrous cycles after
exposure to 25 mg/km3 through inhalation, or oral doses
greater than 1000 mg/kg/d in Wistar and Sprague–Dawley
rats, and in mice (Hirosawa et al., 2006; Ma et al., 2006;
Moyer & Hixon, 2012; Takai et al., 2009). On the other hand,
another study reported no change in estrous cyclicity at
doses up to 405 mg/kg/d in Wistar rats (Grande et al., 2007).
At higher doses, ovulation was suppressed by oral DEHP
exposure (2000 mg/kg/d) in Sprague–Dawley rats (Davis
et al., 1994a). In a similar study with the same maximum
dose, no change in forced ovulation in Fischer 344 rats as
a result of subcutaneous DEHP treatment for 4 d was
demonstrated (Sekiguchi et al., 2006). Taken together, these
data suggest that the adverse effects of DEHP may be at the
level of the hypothalamus or pituitary.
DEHP exposure has also been shown to adversely affect
the morphology of the female reproductive tract. Greater
numbers of atretic follicles and vacuolization of stromal cells
was found in Wistar and Sprague–Dawley rats exposed to
DEHP doses between 300 and 405 mg/kg/d (Grande et al.,
2007; Takai et al., 2009). Additionally, epithelial thinning,
decreased corpora lutea and uterine atrophy have also been
described in rats exposed to 3000 mg/kg/d (Takai et al., 2009).
Conversely, an increase in the weight of the uterus and ovaries
was found when marmosets were exposed to 500 and
2500 mg/kg/d (Tomonari et al., 2006). Although the results
of these two studies differ, we note that different animal
models were used and that marmosets are recognized to be
less sensitive. Therefore we conclude that DEHP exposure
adversely affects estrous cycle length and reproductive organ
structure.
In summary, DEHP exposure can affect reproductive organ
structure, and function as shown by changes in circulating
reproductive hormone concentrations, oocyte health, ovula-
tion, fertility and progression of pregnancy in adult mice and
rats. Two studies have reported a NOAEL of 5 mg/kg/d orally
for female pups exposed in utero (Grande et al., 2006;
Pocar et al., 2012) whereas the NOAEL reported in female
prepubescent rats was approximately 1 mg/kg/d through
inhalation (Ma et al., 2006). In adult females, inhalation and
subcutaneous DEHP exposure resulted in NOAELs that were
11–18 and 250 mg/kg/d, respectively (Klimisch et al., 1992;
Sekiguchi et al., 2006). While there is a large difference
between these values, the LOAELs in the studies were
230–360 and 500 mg/kg/d respectively (Klimisch et al., 1992;
Sekiguchi et al., 2006). Based on these studies, we suggest
a NOAEL of 1.0 mg/kg/d.
Diheptyl phthalate
In the only study found in our search, diheptyl phthalate
(DHPP) exposure had no effect on body weight, number of
implantations, number of live fetuses or number of resorp-
tions in pregnant Sprague–Dawley rats exposed orally to
1000 mg/kg/d (Saillenfait et al., 2011a) although there was a
trend for decreased pup weight (Saillenfait et al., 2011a).
While this is only one study, the results suggest that DHPP is
neither a reproductive nor developmental toxicant.
Di-isoheptyl phthalate
Only one study describing the effects of di-isoheptyl phthalate
(DiHP) was found. In this study, Crl:CDBR VAF/Plus rats
were treated with 100, 300 or 750 mg/kg/d by gavage during
gestation, or administered DiHP in the diet at concentrations
of 1000, 4500 or 8000 ppm over two generations (McKee
et al., 2006). Decrease in weight gain during pregnancy as
well as decreased fetal viability and increased malformations
were found with exposure to 750 mg/kg/d DiHP (McKee
et al., 2006). Exposure to lower doses in the diet (1000 ppm
equivalent to 64–144 mg/kg/d) had no effect on body weight
or fertility, and the number of offspring (McKee et al.,
2006). However, females exposed in utero to 8000 ppm
had decreased fertility and the pups of females exposed
in utero to 4500 or 8000 ppm (approximately 304–716 or
532–1289 mg/kg/d) had decreased weights compared to
controls (McKee et al., 2006). Overall, while adverse effects
on the female reproductive system occurred, they did so at
relatively high doses.
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Di-n-octyl phthalate
We reviewed two studies which examined the effects of
di-n-octyl phthalate (DnOP) on the female reproductive
system. In one study, there was no effect on fertility in
the first or second generation of Swiss CD-1 mice exposed
to DnOP at doses up to 5% in the diet (approximately
7500 mg/kg/d) (Heindel et al., 1989). Additionally, there was
no change in body weight or in the estrous cycle character-
istics (Heindel et al., 1989). Furthermore, a second study
reported no changes in the number of implantations, live
fetuses, resorptions or the number of malformations after oral
exposure of pregnant Sprague–Dawley rats to 1000 mg/kg/d
from GD6-20 (Saillenfait et al., 2011a). Although the
literature is sparse, data suggest that DnOP is neither a
reproductive nor developmental toxicant.
Di-isononyl phthalate
Three studies examining the effects of di-isononyl phthalate
(DiNP) on the female reproductive system were found. In one
study, oral exposure to DiNP had no effect on pregnancy in
Sprague–Dawley rats at doses from 250 to 750 mg/kg/d but
increased male pup weights at 250 mg/kg/d (Adamsson et al.,
2009). Similarly, another study reported no significant effects
on pregnancy in Wistar rats as determined by body weights,
gestation length, number of pups and post-implantation loss
at oral doses from 300 to 900 mg/kg/d (Boberg et al., 2011).
Likewise, a third study in Sprague–Dawley rats found no
effect on pregnancy except for a trend for decreased pup
weight at 0.4% and 0.8% in the diet; however, this effect was
attributed in some cases to an increased number of pups
per litter (Waterman et al., 2000). This study also reported
decreased pup weights at doses from 0.5% in the
diet, decreased maternal weight at 1% in the diet as well as
decreased ovarian weight and decreased survival of pups at
1.5% in the diet (Waterman et al., 2000). Overall, these
studies indicate that there are no important adverse effects of
DiNP exposure on pregnancy.
Di-isodecyl phthalate
Only one study investigating di-isodecyl phthalate (DiDP) and
female reproductive health was found. The estrous cycle and
number of oocytes in Sprague–Dawley rats were unaffected
after exposure to DiDP at doses from 0.02% to 0.8% in the
diet over two generations (Hushka et al., 2001). On the other
hand, the number of pups and pup survival was decreased at
0.8% in the first generation and at 0.4% and 0.8% in the
second generation, and vaginal opening was delayed in the
0.4% and 0.8% exposure groups (Hushka et al., 2001). Despite
a paucity of studies, we suggest that DiDP exposure can
adversely affect pregnancy and female reproductive health.
Di-C7-C9 alkyl phthalate and di-C9-C11 alkyl phthalate
Two articles examining the effects of di-C7–C9 alkyl phthalate
(D79P) and di-C9–C11 alkyl phthalate (D911P) on the female
reproductive system were reviewed. No significant effect
of D79P or D911P on pregnancy was reported at doses up to
1000 mg/kg/d by gavage during gestation or 1% in diet over
two generations in Sprague–Dawley rats (Fulcher et al., 2001;
Willoughby et al., 2000). A dose-dependent relationship with
the incidence of supernumerary ribs in the pups was noted
(Fulcher et al., 2001). However, this was the only important
significant effect in this study (Fulcher et al., 2001). Gestation
length was decreased in the first generation of animals in
the other study (Willoughby et al., 2000); however, gestation
length was unaffected in the second generation. There was no
change in the estrous cycle (Willoughby et al., 2000).
Similarly, in the second generation of animals, there was
no significant difference in the onset of sexual maturity
(Willoughby et al., 2000). Interestingly, in the second
generation, ovarian weights were decreased after exposure
to D79P and uterine weights were decreased after exposure to
D911P (Willoughby et al., 2000). However, these effects are
thought to be random as they are not consistent between
phthalate diesters or generations.
Diallyl phthalate
Only one article regarding the effects of diallyl phthalate
(DAP) on reproductive health was found and revealed
decreased body weight and food consumption, and two
premature births in Sprague–Dawley rats exposed to oral
doses of 200 mg/kg/d DAP or higher during gestation
(Saillenfait et al., 2008a). Fetal weights were decreased in
the 250 mg/kg/d treatment group whilst there was no change
in fertility, litter size or post-implantation loss in any
treatment groups (Saillenfait et al., 2008a). Furthermore, no
increases in external, internal or skeletal malformations were
found (Saillenfait et al., 2008a). Therefore we suggest that
DAP may have a negative effect on pregnancy but is not
teratogenic at low doses. However, the reproductive tract was
not rigorously examined, hence definitive conclusions cannot
be made. Thus, we suggest that, on the basis of this single
study, DAP is unlikely to be a reproductive or developmental
toxicant.
Summary and conclusions
There is compelling evidence of widespread human exposure
to phthalates and some phthalate-containing medications
result in much higher exposures than seen in the general
population. The epidemiological literature fails to reveal an
association with increased risk for endometriosis, breast
cancer and precocious puberty. However, these studies are
plagued by inadequate sample size, methodological issues and
potential misclassification errors. Future studies are needed to
clarify any potential associations between phthalate exposure
and these reproductive health concerns. Furthermore, we
suggest that the epidemiological literature supports a weak
potential relationship between phthalate exposure and sub-
fertility, pregnancy loss, pre-term birth and decreased birth
weight that merits further investigation.
A relatively robust literature was found for DBP, BBP and
DEHP; however, the literature was sparse for less well-known
phthalates including DiBP and DPP. Furthermore, the animal
literature has shown that adverse reproductive effects occur at
high doses whereas concentrations representative of human
exposure do not produce reproductive or developmental
effects. The relevance of current animal models is question-
able. Rats are strongly affected by phthalates through
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peroxisome proliferating pathways which are not relevant
in humans (Ito & Nakajima, 2008; Rusyn & Corton, 2011;
Ward et al., 1998). While phthalates can affect the repro-
ductive system through other pathways as seen in PPARa null
mice (Peters et al., 1997; Ward et al., 1998), the majority of
the animal studies have been conducted in wild-type mice
or rats. Therefore, the effects seen in animal studies may be
completely or in part the result of pathways not important
in humans. As it is impossible to determine which effects
are due to the PPAR pathways and which may occur
in humans, all the results are of questionable relevance.
A different animal model, marmosets, has different problems.
When excretion of phthalates in marmosets was measured,
only a small percentage was found in the urine although the
metabolites were conjugated to glucuronic acid, as is seen in
humans (Kurata et al., 2012; Rhodes et al., 1986). However,
as the pattern of excretion is different from that seen in
humans, who excrete the majority of phthalate metabolites
in urine, it is possible that marmosets absorb phthalates
differently and thus may be less sensitive to phthalates.
Overall, while important data gaps remain, the weight-
of-evidence suggests that phthalates may not significantly
affect the female reproductive system of women in the general
population who are only exposed to low concentrations of
phthalates. The potential for adverse effects resulting from
higher exposure and through interaction with other phthalates
and chemicals is unknown, and thus continues to present a
concern.
Future directions
While the documented adverse effects of phthalates occur at
concentrations above those representative of human exposure,
we suggest that further study is needed to resolve concerns
arising from exposure through medications in which phthal-
ates are used in the manufacture of slow release capsules. We
also suggest that measurement of phthalate metabolites in
urine and target tissues of the treated animals could provide
useful data for comparison with data from human biomonitor-
ing studies. Results of such studies will enhance translation of
results to humans and comparison of findings with those of
epidemiological studies and help reduce uncertainties in risk
assessment.
Studies to date have focused almost exclusively on
exposure to single phthalate metabolites. Although this is
understandable, evidence that phthalates may act in an
additive manner suggest that studies involving exposure to
mixtures of phthalates representative of human exposure are
needed to better understand potential human health risks.
Furthermore, the interaction of phthalate metabolites with
other contaminants widely documented in human biomonitor-
ing studies would also contribute to greater confidence in
existing NOAELs and calculated reference fixed doses.
Results of transgenerational studies suggest that offspring
may be more sensitive to subsequent exposure to phthalates
than parental animals. Therefore, future studies should better
define the effects of phthalate exposure in the offspring of
animals exposed in utero and determine whether or not the
LOAEL decreases in subsequent generations. These results
suggest potential epigenetic mechanisms that are yet to be
explored in relation to phthalate exposure. The concentration
of phthalates needed to induce epigenetic changes should be
defined in order to better understand potential implications to
human health. Moreover, the health implication of changes
in epigenetic signatures also needs to be better developed.
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